{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:16Z","timestamp":1792521436771,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.02.013","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T15:48:50Z","timestamp":1613922530000},"page":"1758-1764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity and safety profiles of a new MAV\/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study"],"prefix":"10.1016","volume":"39","author":[{"given":"Ui Yoon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6039-2224","authenticated-orcid":false,"given":"Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Wook","family":"Eun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyuk","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-5924","authenticated-orcid":false,"given":"Keswadee","family":"Lapphra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auchara","family":"Tangsathapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pope","family":"Kosalaraksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peninnah","family":"Oberdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwang Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Son Moon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Han","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.013_b0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1089\/vim.2017.0136","article-title":"Varicella virus vaccination in the United States","volume":"31","author":"Shaw","year":"2018","journal-title":"Viral Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.02.013_b0010","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0163-4453(17)30188-3","article-title":"Is chickenpox so bad, what do we know about immunity to varicella zostervirus, and what does it tell us about the future?","volume":"74","author":"Gershon","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2021.02.013_b0015","series-title":"Plotkin\u2019s Vaccines","first-page":"1145","article-title":"Varicella vaccines","author":"Gershon","year":"2017"},{"key":"10.1016\/j.vaccine.2021.02.013_b0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","article-title":"Varicella vaccination - the global experience","volume":"16","author":"Wutzler","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.013_b0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2051013613515621","article-title":"Successes and challenges in varicella vaccine","volume":"2","author":"Papaloukas","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.013_b0030","first-page":"645","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"Varela","year":"2019","journal-title":"HumVaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.013_b0035","unstructured":"World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec 2014;89:265\u201387."},{"key":"10.1016\/j.vaccine.2021.02.013_b0040","doi-asserted-by":"crossref","unstructured":"Choi UY, Huh DH, Kim JH, Kang JH. Seropositivity of varicella zoster virus in vaccinated Korean children and MAV vaccine group. Hum Vaccin Immunother 2016;12:2560\u20134. http:\/\/doi.org\/10.1080\/21645515.2016.1190056.","DOI":"10.1080\/21645515.2016.1190056"},{"key":"10.1016\/j.vaccine.2021.02.013_b0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/1743-422X-8-547","article-title":"Sequencing and characterization of varicella-zoster virus vaccine strain SuduVax","volume":"8","author":"Kim","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2021.02.013_b0050","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1080\/21645515.2015.1009811","article-title":"Characteristics and viral propagation properties of a new human diploid cell line, Walvax-2, and its suitability as a candidate cell substrate for vaccine production","volume":"11","author":"Ma","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.013_b0055","unstructured":"Ministry of Korean Food and Drug Safety. Multi-National Vaccine Clinical Trial Protocol. 1st ed. Cheongju (KR): Ministry of Korean Food and Drug Safety, 2016:377\u2013445."},{"key":"10.1016\/j.vaccine.2021.02.013_b0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/130.6.669","article-title":"Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence","volume":"130","author":"Williams","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.013_b0065","unstructured":"National Institute for Biological Standards and Control. The first international standard for varicella immunoglobulin (1987). WHO Technical Report Series version 4.0. NIBSC code W1044. https:\/\/www.nibsc.org\/documents\/ifu\/W1044.pdf [accessed January 4, 2021]."},{"key":"10.1016\/j.vaccine.2021.02.013_b0070","unstructured":"Medical Dictionary for Regulatory Activities. http:\/\/meddra.org [accessed July 29, 2020]."},{"key":"10.1016\/j.vaccine.2021.02.013_b0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.24953\/turkjped.2018.01.008","article-title":"Outbreak of varicella in preschool children despite one-dose vaccination","volume":"60","author":"Kurugol","year":"2018","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.vaccine.2021.02.013_b0080","unstructured":"Lee JY, Jeong HJ, Kim SJ, Yu JH, Kim GH; Korean Centers for Disease Control and Prevention (KCDC). National childhood vaccination coverage among children aged 1-3 and 6 years in Korea, 2018. PHWR Public Health Wkly Rep 2019;12:1548\u201358. [In Korean]."},{"key":"10.1016\/j.vaccine.2021.02.013_b0085","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1080\/21645515.2019.1603985","article-title":"Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003\u20132015","volume":"15","author":"Choi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.013_b0090","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1017\/S0950268819001389","article-title":"Increasing varicella incidence rates among children in the Republic of Korea: an age-period-cohort analysis","volume":"147","author":"Lee","year":"2019","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2021.02.013_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jinf.2010.04.001","article-title":"Seroprevalence rate after onedose of varicella vaccine in infants","volume":"61","author":"Kim","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2021.02.013_b0100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children","volume":"197","author":"Michalik","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.013_b0105","doi-asserted-by":"crossref","unstructured":"Morino S, Tanaka-Taya K, Satoh H, Arai S, Takahashi T, Sunagawa T, et al. Descriptive epidemiology of varicella based on national surveillance data before and after the introduction of routine varicella vaccination with two doses in Japan, 2000-2017.Vaccine 2018;36:5977\u201382. http:\/\/doi.org\/10.1016\/j.vaccine.2018.08.048.","DOI":"10.1016\/j.vaccine.2018.08.048"},{"key":"10.1016\/j.vaccine.2021.02.013_b0110","first-page":"604","article-title":"Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trials, 1987 to 1989","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.02.013_b0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.88.3.604","article-title":"Immunogenicity of subcutaneous versus intramuscular Oka\/Merck varicella vaccination in healthy children","volume":"88","author":"Dennehy","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.02.013_b0120","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/529044","article-title":"Second dose of varicella vaccine for children: are we giving it too late?","volume":"197","author":"Shapiro","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.013_b0125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/CVI.00645-13","article-title":"Varicella and varicella vaccination in South Korea","volume":"21","author":"Oh","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.02.013_b0130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/422454","article-title":"Fever after immunization: current concepts and improved future scientific understanding","volume":"39","author":"Kohl","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.013_b0135","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy trial in healthy children","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.013_b0140","unstructured":"Lopez A, Leung J, Schmid S, Marin M. Centers for Disease Control and Prevention. Chapter 17: Varicella. In: Roush SW, Baldy LM, Hall MAK, eds. Manual for Surveillance of Vaccine-Preventable Disease. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt17-varicella.pdf [accessed July 29, 2020]."},{"key":"10.1016\/j.vaccine.2021.02.013_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0264-410X(91)90266-9","article-title":"Antibody assays suitable for assessing immune responses to live varicella vaccine","volume":"9","author":"Provost","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.013_b0150","doi-asserted-by":"crossref","first-page":"e00296","DOI":"10.1128\/JCM.00296-19","article-title":"Calibration and evaluation of quantitative antibody titers for varicella-zoster virus by use of the bioplex 2200","volume":"57","author":"McLachlan","year":"2019","journal-title":"J Clin Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:30Z","timestamp":1759402410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001614"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety profiles of a new MAV\/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}